| Development update
Eli Lilly has a phase 2 trial of bimagrumab in heart failure on ClinicalTrials.gov, NCT07920887, called ACTIVATE-HFpEF. The Atlas checked the record on November 9, 2026. It lists the study as not yet recruiting. The trial is randomized, double-blind and placebo-controlled, and plans to enroll 540 adults.
It is aimed at heart failure with preserved ejection fraction (HFpEF), where symptoms of heart failure are present but the heart's pumping fraction is normal. Participants must be 18 or older with a BMI of at least 23, an ejection fraction of 50% or higher, and New York Heart Association class II to III symptoms. They also need a Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) of 80 or lower and a six-minute walk distance of 100 to 450 meters. Participation lasts about 76 weeks.
The primary outcome is the change in KCCQ-CSS, a patient-reported measure of symptoms and function, at week 52. Secondary outcomes include six-minute walk distance, hs-CRP (a blood marker of inflammation), the share of people with a meaningful improvement in KCCQ and walking distance, E/e' (an ultrasound measure of heart filling pressure) and total body lean mass.
The record gives a start in November 2026, primary completion in July 2029 and study completion in November 2029. It lists nine sites: Van Nuys, California; North Miami Beach, Florida; Dallas, Texas; Budapest; Caserta and Torino in Italy; and Krakow and Wroclaw (two sites) in Poland.
Worth knowing: The record lists no dose, route or schedule for bimagrumab. A registry entry says a study is planned. It does not say the study will produce results, or that the medicine works in heart failure. Bimagrumab is an antibody that the Atlas covers in its guide to protecting muscle on GLP-1 medicines.
Related: Protecting muscle on GLP-1 medicines | Pipeline | Lilly tracker | LY4247147 phase 1 trial
Source: ClinicalTrials.gov, ACTIVATE-HFpEF (NCT07920887) Trial registry.